<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529554</url>
  </required_header>
  <id_info>
    <org_study_id>CLEVER-ACS</org_study_id>
    <nct_id>NCT01529554</nct_id>
  </id_info>
  <brief_title>Controlled Level EVERolimus in Acute Coronary Syndromes</brief_title>
  <acronym>CLEVER-ACS</acronym>
  <official_title>Phase I-II Randomized Prospective Double-blind Multi-center Trial on the Effects of a Short Course of Oral Everolimus on Infarct Size, Left Ventricular Remodeling and Inflammation in Patients With Acute ST-Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myocardial infarction (AMI) constitutes the major cause of death in most nations and&#xD;
      death rates and morbidity remain substantial in the years thereafter. Inflammation is a&#xD;
      hallmark throughout the distinct stages of atherosclerotic lesion formation preceding AMI as&#xD;
      well as at the time of plaque rupture and during the post-infarct repair phase. Harnessing&#xD;
      its harmful consequences constitutes an attractive therapeutic approach to address this unmet&#xD;
      medical need.&#xD;
&#xD;
      The objectives of this study are to evaluate the effects of mTOR inhibition (everolimus) on&#xD;
      infarct size, myocardial function and inflammation in patients with ST-Elevation Myocardial&#xD;
      Infarction.&#xD;
&#xD;
      The efficacy objectives are:&#xD;
&#xD;
        1. (1° endpoint):&#xD;
&#xD;
           To assess the effect of mTOR inhibition (everolimus) on myocardial infarct size as&#xD;
           change from baseline (12-72 hours after percutaneous coronary intervention) to 30 days&#xD;
           follow-up measured by MRI (Late Gadolinium Enhancement (LGE) for transmurality).&#xD;
&#xD;
        2. (2° endpoint):&#xD;
&#xD;
           To evaluate microvascular obstruction (MVO) as change from baseline (12-72 hours after&#xD;
           percutaneous coronary intervention) to 30 days follow-up evaluated by MRI.&#xD;
&#xD;
        3. (3° endpoints):&#xD;
&#xD;
             1. Change of left ventricular volume from baseline (12-72 hours after percutaneous&#xD;
                coronary intervention) to 30 days follow-up measured by MRI.&#xD;
&#xD;
             2. Change of biomarkers from time of coronary angiography to 30 days follow-up&#xD;
                including a time-course (AUC). Biomarkers comprise hs-TnT, NT-proBNP, hs-CRP, IL-6&#xD;
                and inflammatory biomarkers OPG, sRANKL, OPN and CCN1.&#xD;
&#xD;
      The safety objectives are:&#xD;
&#xD;
      To explore the effect of mTOR inhibition (everolimus) on several clinical and safety&#xD;
      laboratory parameters including plasma lipid levels and blood count. This will be&#xD;
      complemented by analysis of inflammatory cell subsets in coronary thrombi and peripheral&#xD;
      blood (CD4+ T helper lymphocyte subsets, monocyte subsets).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 8, 2015</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarct size measured by MRI</measure>
    <time_frame>Change from baseline at 30 days</time_frame>
    <description>To assess the effect of mTOR inhibition (everolimus) on myocardial infarct size as measured by MRI (Late Gadolinium Enhancement (LGE) for infarct size (transmurality) at 12-72 h (baseline) and 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction (MVO) measured by MRI</measure>
    <time_frame>Change from baseline at 30 days</time_frame>
    <description>To evaluate microvascular obstruction (MVO) by MRI at 12-72 h (baseline) and 30 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Left ventricular volume measured by MRI</measure>
    <time_frame>Change from baseline at 30 days</time_frame>
    <description>To evaluate left ventricular volume by MRI at 12-72 h (baseline) and 30 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers</measure>
    <time_frame>Change from baseline at 30 days including time course</time_frame>
    <description>To evaluate the changes of left ventricular volume from baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus p.o. for 5 days (d0=7.5 mg, d1=7.5 mg, d2=7.5 mg, d3=5 mg, d4=5mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator with identical composition of tablets except everolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)</description>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo tablets manufactured to be identical to verum tablets except content of everolimus</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Elevation Myocardial Infarction (STEMI) as defined by:&#xD;
&#xD;
               -  ST-Elevation &gt; 1mm in &gt; 2 leads OR&#xD;
&#xD;
               -  Novel left bundle branch block (LBBB) OR&#xD;
&#xD;
               -  Posterior MI with ST-Depression &gt; 1mm in &gt; 2 leads&#xD;
&#xD;
          2. Chest pain duration of &gt; 10 minutes&#xD;
&#xD;
          3. Primary Coronary Intervention (PCI) with drug-eluting stent (DES) within 24 hours of&#xD;
             chest pain onset in the occluded culprit artery&#xD;
&#xD;
          4. First Myocardial Infarction&#xD;
&#xD;
          5. Occluded coronary artery at angiography specifically occlusion of one coronary vessel&#xD;
             in the proximal third of either LAD, RCX or RCA, the mid segment of right coronary&#xD;
             artery (RCA) or mid segment of a large left anterior descending (LAD) coronary artery,&#xD;
             i.e. when the latter reaches the apex.&#xD;
&#xD;
          6. Male and female patients 18 years to 90 years of age&#xD;
&#xD;
          7. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another drug or stent trial&#xD;
&#xD;
          2. Pregnant women or nursing mothers&#xD;
&#xD;
          3. Mechanical complication during acute coronary syndrome&#xD;
&#xD;
          4. Scheduled PCI for additional lesion within 30 days&#xD;
&#xD;
          5. Multivessel disease&#xD;
&#xD;
          6. Major elective surgery planned in trial period&#xD;
&#xD;
          7. Malignancy (unless healed or remission &gt; 5 years)&#xD;
&#xD;
          8. Chronic infection (HIV, Tbc, empyema)&#xD;
&#xD;
          9. Severely compromised renal function (GFR&lt; 30 ml/min)&#xD;
&#xD;
         10. Positive PCR Test for SARS-CoV-2 and/or at least one positive answer to questions&#xD;
             regarding symptoms/contact related to COVID-19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Ruschitzka, Professor</last_name>
    <role>Study Director</role>
    <affiliation>UniversityHospitalZurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kerckhoff-Klinik, Department of Cardiology</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Chartié</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Duesseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndromes</keyword>
  <keyword>ST-Elevation Myocardial Infarction</keyword>
  <keyword>Infarct size</keyword>
  <keyword>inflammation</keyword>
  <keyword>everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

